{"&cites=16232844485483822153&as_sdt=2005&sciodt=0,5&hl=en":[{"title":"Safety, activity, and immune correlates of anti–PD-1 antibody in cancer","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1200690","authors":["SL Topalian","SL Topalian FS Hodi","SL Topalian FS Hodi JR Brahmer…"],"year":2012,"numCitations":9272,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1200690","citationUrl":"http://scholar.google.com/scholar?cites=10859371970938450815&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:f7Oeq0U9tJYJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=10859371970938450815&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc","p":1,"exp":1596365388745},{"title":"The blockade of immune checkpoints in cancer immunotherapy","url":"https://www.nature.com/articles/nrc3239/","authors":["DM Pardoll"],"year":2012,"numCitations":7743,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4856023/","citationUrl":"http://scholar.google.com/scholar?cites=11484971735372092127&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:31JBfvHQYp8J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=11484971735372092127&hl=en&as_sdt=2005&sciodt=0,5","publication":"nature.com"},{"title":"Safety and activity of anti–PD-L1 antibody in patients with advanced cancer","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1200694","authors":["JR Brahmer","JR Brahmer SS Tykodi","JR Brahmer SS Tykodi LQM Chow…"],"year":2012,"numCitations":5905,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1200694","citationUrl":"http://scholar.google.com/scholar?cites=13360512895833832804&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:ZH0zFbETarkJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=13360512895833832804&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"PD-1 and its ligands in tolerance and immunity","url":"https://www.annualreviews.org/doi/abs/10.1146/annurev.immunol.26.021607.090331","authors":["ME Keir","ME Keir MJ Butte","ME Keir MJ Butte GJ Freeman…"],"year":2008,"numCitations":3819,"pdf":"https://www.annualreviews.org/doi/full/10.1146/annurev.immunol.26.021607.090331?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&","citationUrl":"http://scholar.google.com/scholar?cites=6818767428197913359&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:D5O9O9kgoV4J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=6818767428197913359&hl=en&as_sdt=2005&sciodt=0,5","publication":"annualreviews.org"},{"title":"Pembrolizumab for the treatment of non–small-cell lung cancer","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1501824","authors":["EB Garon","EB Garon NA Rizvi","EB Garon NA Rizvi R Hui","EB Garon NA Rizvi R Hui N Leighl…"],"year":2015,"numCitations":3628,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1501824","citationUrl":"http://scholar.google.com/scholar?cites=4804110826968085903&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:j3UKB1ihq0IJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=4804110826968085903&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","url":"https://www.sciencedirect.com/science/article/pii/S0140673615012817","authors":["RS Herbst","RS Herbst P Baas","RS Herbst P Baas DW Kim","RS Herbst P Baas DW Kim E Felip","RS Herbst P Baas DW Kim E Felip JL Pérez"],"year":2016,"numCitations":3443,"pdf":"https://www.researchgate.net/profile/Marcelo_Garrido/publication/287505140_Pembrolizumab_versus_docetaxel_for_previously_treated_PD-L1-positive_advanced_non-small-cell_lung_cancer_KEYNOTE-010_A_randomised_controlled_trial/links/5cddf42d299bf14d959f721f/Pembrolizumab-versus-docetaxel-for-previously-treated-PD-L1-positive-advanced-non-small-cell-lung-cancer-KEYNOTE-010-A-randomised-controlled-trial.pdf","citationUrl":"http://scholar.google.com/scholar?cites=10642977900179326521&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:OYaF5AJ0s5MJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=10642977900179326521&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","url":"https://www.nature.com/articles/nature14011?page=1","authors":["RS Herbst","RS Herbst JC Soria","RS Herbst JC Soria M Kowanetz","RS Herbst JC Soria M Kowanetz GD Fine","RS Herbst JC Soria M Kowanetz GD Fine O Hamid…"],"year":2014,"numCitations":3074,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4836193/","citationUrl":"http://scholar.google.com/scholar?cites=16172811975131816039&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:Z2Dq3M1eceAJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16172811975131816039&hl=en&as_sdt=2005&sciodt=0,5","publication":"nature.com"},{"title":"The B7 family revisited","url":"https://www.annualreviews.org/doi/abs/10.1146/annurev.immunol.23.021704.115611?url_ver=Z39.88-2003&rfr_dat=cr_pub%3Dpubmed&rfr_id=ori%3Arid%3Acrossref.org&journalCode=immunol","authors":["RJ Greenwald","RJ Greenwald GJ Freeman","RJ Greenwald GJ Freeman AH Sharpe"],"year":2005,"numCitations":2569,"citationUrl":"http://scholar.google.com/scholar?cites=15697575036091849830&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:ZlxLdVP92NkJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=15697575036091849830&hl=en&as_sdt=2005&sciodt=0,5","publication":"annualreviews.org"},{"title":"Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic …","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4834717/","authors":["JR Brahmer","JR Brahmer CG Drake","JR Brahmer CG Drake I Wollner…"],"year":2010,"numCitations":2416,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4834717/","citationUrl":"http://scholar.google.com/scholar?cites=10977515176452218091&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:69zkQOT3V5gJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=10977515176452218091&hl=en&as_sdt=2005&sciodt=0,5","publication":"ncbi.nlm.nih.gov"},{"title":"The future of immune checkpoint therapy","url":"https://science.sciencemag.org/content/348/6230/56.abstract","authors":["P Sharma","P Sharma JP Allison"],"year":2015,"numCitations":2223,"citationUrl":"http://scholar.google.com/scholar?cites=1385363128569161210&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:-uVJ62zMORMJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1385363128569161210&hl=en&as_sdt=2005&sciodt=0,5","publication":"science.sciencemag.org"}]}